DAX19.984 +0,7%ESt504.899 +0,8%Top 10 Crypto14,75 +0,5%Dow42.992 -0,8%Nas19.722 -1,5%Bitcoin89.804 ±0,0%Euro1,0425 ±-0,0%Öl74,25 +0,3%Gold2.624 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Lilium A3CYXP NVIDIA 918422 Novo Nordisk A3EU6F Tesla A1CX3T Bayer BAY001 Allianz 840400 Amazon 906866 Apple 865985 Volkswagen (VW) vz. 766403 BASF BASF11 Rheinmetall 703000 Microsoft 870747 Mercedes-Benz Group (ex Daimler) 710000 Xiaomi A2JNY1 Palantir A2QA4J
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Ruhiger Handel: Dow schließt tiefer -- DAX letztlich in Grün -- Delivery Hero darf Food Panda-Taiwan nicht an Uber verkaufen -- HelloFresh plant Rückkauf eigener Aktien -- Xiaomi, VW im Fokus
Top News
Analyst warnt vor Korrektur des S&P 500: Darum könnte der US-Aktienmarkt 2025 fallen Analyst warnt vor Korrektur des S&P 500: Darum könnte der US-Aktienmarkt 2025 fallen
Krypto-Boom: Diese Bitcoin-Prognosen für 2025 sprengen alle Erwartungen Krypto-Boom: Diese Bitcoin-Prognosen für 2025 sprengen alle Erwartungen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
+++ Einfach investieren ▪ mit Kapitalschutz oder Teilschutz ▪ raiffeisenzertifikate.at ▪ jetzt in Zeichnung +++

Johnson Johnson Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
138,98 EUR +0,40 EUR +0,29 %
STU
145,19 USD +0,10 USD +0,07 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.334,86 Mrd. EUR

KGV28,32Div. Rendite3,00%

WKN853260

ISINUS4781601046

SymbolJNJ

Johnson Johnson Aktien News

DatumMeistgelesen
PR NewswireHealth Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer wit...
PR NewswireCARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
PR NewswireNipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
PR NewswireJohnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease
PR NewswireTREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
PR NewswireSubcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
PR NewswireLate-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study
PR NewswireTALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
PR NewswireSarepta Therapeutics Set to Join S&P MidCap 400
PR NewswireCARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
PR NewswireALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Shockwave Medical, Inc.
PR NewswireRYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mu...
PR NewswireTECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
PR NewswireAMBRX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
MyDividendsJohnson & Johnson gibt vierteljährliche Dividende bekannt
PR NewswireCIBC introduces additional Canadian Depositary Receipts ("CDRs")
PR NewswireCIBC introduces additional Canadian Depositary Receipts ("CDRs")
PR NewswireKenvue Set to Join S&P 500; Advance Auto Parts to Join S&P SmallCap 600
PR NewswireKenvue Set to Join S&P 500
MyDividendsJohnson & Johnson erhöht die Dividende das 61. Jahr in Folge
MyDividendsJohnson & Johnson zahlt seit 1944 eine Dividende an die Investoren
PR NewswireSteel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400
PR NewswireYouth at Risk of Being Left Behind in Asia Pacific Tuberculosis Response, Regional Forum Spotlights
RSSForm 4 200406
RSSForm SC TO-T 200406
RSSForm SC TO-C 200406
RSSForm 4 200406
RSSForm SC TO-C 200406
RSSForm 4 200406
RSSForm 3 200406
MyDividendsJohnson & Johnson zahlt Dividende für das dritte Quartal aus
PR NewswireJohnson & Johnson Ends Global Sales of Cancer-Causing Baby Powder Amid Increased Scrutiny from Consumer Litigation, Science
PR NewswireJohnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research
PR NewswireJohnson & Johnson Releases 2021 Health for Humanity Report Highlighting Performance on ESG Priorities and Progress Against Public Commitments
PR NewswireJohnson & Johnson to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
PR NewswireJohnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company
PR NewswireJohnson & Johnson to Participate in the Bernstein 38th Annual Strategic Decisions Conference
PR NewswireJohnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR)
PR NewswireJohnson & Johnson to Participate in the UBS Global Healthcare Conference
MyDividendsJohnson & Johnson steigert die Dividende das 60. Jahr in Folge

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.